Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435992 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,012
- Enrollment target
NCT02435992: Completed Phase 3 study, sponsored by Celgene.
NCT02435992 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,012 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02435992, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,012 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Primary Outcome
Percentage of participants that are in Clinical remission at 10 weeks
Interventions
- DRUG Placebo
- DRUG RPC1063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2015-06-17 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 3 |
What the finished NCT02435992 record still lists
NCT02435992 is an interventional study that assigns participants to a tested intervention. Its 1,012 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02435992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02435992 about?
NCT02435992 is a clinical study titled "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis". The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
What is the current status of trial NCT02435992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,012 participants. The study started on 2015-06-17. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT02435992?
The interventions under investigation include: Placebo (DRUG), RPC1063 (DRUG).
Who is sponsoring clinical trial NCT02435992?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02435992's enrollment target sits among peer trials
1,012 294th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI